Von Hoff DD - Search Results

1

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Burris HA 3rd, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD. Burris HA 3rd, et al. Among authors: von hoff dd. Anticancer Drugs. 1994 Aug;5(4):394-402. doi: 10.1097/00001813-199408000-00002. Anticancer Drugs. 1994. PMID: 7949242 Clinical Trial.

2

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.

Weiss GR, Kuhn JG, Rizzo J, Smith LS, Rodriguez GI, Eckardt JR, Burris HA 3rd, Fields S, VanDenBerg K, von Hoff DD. Weiss GR, et al. Among authors: von hoff dd. Cancer Chemother Pharmacol. 1995;35(5):397-402. doi: 10.1007/s002800050253. Cancer Chemother Pharmacol. 1995. PMID: 7850921 Clinical Trial.

3

Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.

Rinaldi DA, Lippman SM, Burris HA 3rd, Chou C, Von Hoff DD, Hong WK. Rinaldi DA, et al. Among authors: von hoff dd. Anticancer Drugs. 1993 Feb;4(1):33-6. doi: 10.1097/00001813-199302000-00004. Anticancer Drugs. 1993. PMID: 8457712 Clinical Trial.

4

A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.

Weiss GR, Shaffer DW, DeMoor C, Rinaldi DA, Rodriguez GI, Eckardt JR, Stephens C, Von Hoff DD. Weiss GR, et al. Among authors: von hoff dd. Anticancer Drugs. 1996 Jun;7(4):402-9. doi: 10.1097/00001813-199606000-00005. Anticancer Drugs. 1996. PMID: 8826608 Clinical Trial.

5

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD. Creemers GJ, et al. Among authors: von hoff dd. J Clin Oncol. 1997 Mar;15(3):1087-93. doi: 10.1200/JCO.1997.15.3.1087. J Clin Oncol. 1997. PMID: 9060549 Clinical Trial.

6

Phase I study with the DNA sequence-specific agent adozelesin.

Burris HA, Dieras VC, Tunca M, Earhart RH, Eckardt JR, Rodriguez GI, Shaffer DS, Fields SM, Campbell E, Schaaf L, Kasunic D, Von Hoff DD. Burris HA, et al. Among authors: von hoff dd. Anticancer Drugs. 1997 Jul;8(6):588-96. doi: 10.1097/00001813-199707000-00006. Anticancer Drugs. 1997. PMID: 9300573 Clinical Trial.

7

Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.

Raymond E, Burris HA, Rowinsky EK, Eckardt JR, Rodriguez G, Smith L, Weiss G, Von Hoff DD. Raymond E, et al. Among authors: von hoff dd. Ann Oncol. 1997 Oct;8(10):1003-8. doi: 10.1023/a:1008253314126. Ann Oncol. 1997. PMID: 9402174 Free article. Clinical Trial.

8

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Burris HA 3rd, Raymond E, Awada A, Kuhn JG, O'Rourke TJ, Brentzel J, Lynch W, King SY, Brown TD, Von Hoff DD. Burris HA 3rd, et al. Among authors: von hoff dd. Invest New Drugs. 1998;16(1):19-27. doi: 10.1023/a:1016066529642. Invest New Drugs. 1998. PMID: 9740540 Clinical Trial.

9

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD. Rinaldi DA, et al. Among authors: von hoff dd. Cancer Chemother Pharmacol. 1999;44(5):372-80. doi: 10.1007/s002800050992. Cancer Chemother Pharmacol. 1999. PMID: 10501910 Clinical Trial.

10

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Wall JG, Burris HA 3rd, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, et al. Wall JG, et al. Among authors: von hoff dd. Anticancer Drugs. 1992 Aug;3(4):337-45. doi: 10.1097/00001813-199208000-00004. Anticancer Drugs. 1992. PMID: 1330081 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

772 results

Search Page

Filters